Given that GSK3B is implicated in development of both Alzheimer’s disease and schizophrenia [9], [17]–[19], [22], this suggests that at least part of the relationship of these disorders with reduced intracranial volume may reflect the impact of GSK3B on brain development. This evidence concerns the gene GSK3B and early-onset autosomal dominant Alzheimer disease.